文献速递瓣膜外科冠心病外科

常规二次生物瓣置换20年以上经验:手术基准应指导经导管瓣中瓣治疗的患者选择

Conventional redo biological valve replacement over 20 years: Surgical benchmarks should guide patient selection for transcatheter valve-in-valve therapy.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-05-31

该研究回顾了1993年1月至2014年7月在本中心接受再次生物瓣置换的694例患者,30天死亡56例(8%),既往冠状动脉旁路移植术(HR 3.5)和纽约心脏协会功能分级(每增加1级,HR 2.1)是早期死亡的独立预测因素,无此组合者30天死亡仅4%。作者认为该结果可为经导管瓣中瓣治疗的患者选择提供手术基准。

要点

  • 再次生物瓣置换术后30天死亡率为8%(56/694)。
  • 既往冠状动脉旁路移植术(HR 3.5)和纽约心脏协会功能分级(每增加1级,HR 2.1)是早期死亡的独立预测因素。
  • 同时具备既往冠状动脉旁路移植术和纽约心脏协会III或IV级者占早期死亡的46%(26/56),无此组合者早期死亡为4%(30/694)。

核心结论

  • 在大量再次生物瓣置换患者中,既往冠状动脉旁路移植术和晚期纽约心脏协会功能分级与30天死亡率增加相关,其余人群30天死亡率低至4%。
  • 该研究可作为手术基准,用于指导经导管瓣中瓣技术的患者选择,而非将这类技术广泛用于那些在常规瓣膜手术后早期死亡风险低且长期生存持久的患者。

研究设计与样本

  • 回顾性研究,纳入1993年1月至2014年7月在本中心接受再次生物瓣置换的694例患者。
  • 再次手术时中位年龄71岁(范围26-95岁),男性437例(63%)。
  • 高血压453例(65%),糖尿病128例(18%),既往心肌梗死85例(12%),既往卒中81例(12%),既往冠状动脉旁路移植术212例(31%)。
  • 中位左心室射血分数41%(范围20-61),纽约心脏协会功能分级III或IV级529例(76%)。

主要发现

  • 再次生物瓣置换最常见为主动脉瓣464例(67%)和二尖瓣170例(24%)。
  • 同期行冠状动脉旁路移植术134例(19%)。
  • 30天死亡56例(8%)。
  • 多变量分析显示纽约心脏协会功能分级(每增加1级)为早期死亡的独立预测因素(HR 2.1,95%CI 1.06-4.3,P=0.03)。
  • 多变量分析显示既往冠状动脉旁路移植术为早期死亡的独立预测因素(HR 3.5,95%CI 1.2-10.9,P=0.03)。

关键数值与推荐

  • 随访在638例早期存活者中可获得602例(94%),中位随访45个月(范围1个月-23.4年)。
  • 5年和10年生存率分别为63%和34%。
  • 随访期间死亡患者的中位术后生存时间为5.5年(最大22年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although primary transcatheter valve interventions have demonstrated acceptable early- and intermediate-term outcomes, data are lacking to guide patient selection for transcatheter valve-in-valve therapy. Furthermore, very few surgical benchmarks have been established for repeat conventional biological valve replacement to refine momentum for broad application of transcatheter intervention for a degenerated bioprosthesis. METHODS: From January 1993 to July 2014, 694 patients underwent repeat biological valve replacement at our clinic. Median age at repeat operation was 71 years (range, 26-95 years) and there were 437 men (63%). Hypertension was present in 453 patients (65%), diabetes in 128 patients (18%), prior myocardial infarction in 85 patients (12%), and prior stroke in 81 patients (12%). Prior coronary bypass grafting was performed in 212 patients (31%). Median left ventricular ejection fraction was 41% (range, 20-61) and New York Heart Association functional class III or IV was present in 529 patients (76%). RESULTS: Biological valve re-replacement included most commonly aortic valve in 464 patients (67%) and mitral valve in 170 (24%). Concomitant coronary bypass grafting was performed in 134 patients (19%). Mortality at 30 days occurred in 56 patients (8%). Multivariable analysis with backward stepwise regression identified New York Heart Association functional class (per 1 increment) (hazard ratio, 2.1; 95% confidence interval, 1.06-4.3; P = .03) and prior coronary bypass grafting (hazard ratio, 3.5; 95% confidence interval, 1.2-10.9; P = .03) as independent predictors of early death. Patients with the combination of prior coronary bypass grafting and New York Heart Association functional class III or IV accounted for 26 out of 56 early deaths (46%) and in the absence of this combination, early death in the cohort was 30 out of 694 (4%). Follow-up was available in 602 out of 638 early survivors (94%) for a median of 45 months (range, 1 month-23.4 years). Survival at 5 and 10 years was 63% and 34%, respectively. For patients who died during follow-up, 2-dimensional scatter plots demonstrate durable length of postoperative survival (median, 5.5 years; maximum, 22 years). CONCLUSIONS: In a large population of patients undergoing repeat biological valve replacement, prior coronary bypass grafting and advanced New York Heart Association functional class were associated with increased 30-day mortality, with the remaining population having a low 30-day mortality of 4%. This study could serve as a surgical benchmark to guide patient selection for transcatheter valve-in-valve technology rather than employing a broader application of these techniques to those who may otherwise have low early risk of mortality and durable long-term survival after conventional valve surgery.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Stulak JM, Tchantchaleishvili V, Daly RC, et al. Conventional redo biological valve replacement over 20 years: Surgical benchmarks should guide patient selection for transcatheter valve-in-valve therapy. J Thorac Cardiovasc Surg. 2018. PMID: 30248789. doi:10.1016/j.jtcvs.2018.03.176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。